Dabrafenib plus trametinib in patients with BRAF.

Subbiah, V; Lassen, U; EElez, E; Italiano, A; Curigliano, G; Javle, M; de Braud, F; Prager, GW; Greil, R; Stein, A; Fasolo, A; Schellens, JHM; Wen, PY; Viele, K; Boran, AD; Gasal, E; Burgess, P; Ilankumaran, P; Wainberg, ZA.

Lancet Oncol. 2020; 21(9):1234-1243.

https://pubmed.ncbi.nlm.nih.gov/32818466/